Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015 Jan-Feb;65(1): 5–29. doi:10.3322/caac.21254. Epub 2015 Jan 5.
   PubMed Web of Science ®Google Scholar
• Mallinson CN, Rake MO, Cocking JB, et al. Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial. Br Med J. 1980;281(6255):1589–1591.
   PubMed Web of Science ®Google Scholar
• Schein PS, Lavin PT, Moertel CG, et al. Randomized phase II clinical trial of adriamycin, methotrexate, and actinomycin-D in advanced measurable pancreatic carcinoma: a gastrointestinal tumor study group report. Cancer. 1978 Jul;42(1):19–22.
   PubMed Web of Science ®Google Scholar
• Kelsen D, Hudis C, Niedzwiecki D, et al. A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma. Cancer. 1991;68(5):965–969.
   PubMed Web of Science ®Google Scholar
• Cullinan S, Moertel CG, Wieand HS, et al. A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. Cancer. 1990;65(10):2207–2212.
   PubMed Web of Science ®Google Scholar
• Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997 Jun;15(6):2403–2413.
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, et al. Groupe tumeurs digestives of unicancer; PRODIGE intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–1825. doi:10.1056/NEJMoa1011923.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013 [Oct 31];369(18):1691–1703. doi:10.1056/NEJMoa1304369. Epub 2013 Oct 16.
   PubMed Web of Science ®Google Scholar
• Pelzer U, Schwaner I, Stieler J, et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer. 2011 Jul;47(11):1676–1681. doi:10.1016/j.ejca.2011.04.011. Epub 2011 May 10.
   PubMed Web of Science ®Google Scholar
• Oettle H, Riess H, Stieler JM, et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol. 2014 [Aug 10];32(23):2423–2429. doi:10.1200/JCO.2013.53.6995. Epub 2014 Jun 30.
   PubMed Web of Science ®Google Scholar
• Gill S, Ko Y-J, Cripps MC, et al. PANCREOX: a randomized phase 3 study of 5FU/LV with or without oxaliplatin for second-line advanced pancreatic cancer (APC) in patients (pts) who have received gemcitabine (GEM)-based chemotherapy (CT). Proc Am Soc Clin Oncol. 2014;32(suppl 5):abstr 4022.
   Google Scholar
• Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005 [May 20];23(15):3509–3516.
   PubMed Web of Science ®Google Scholar
• Ohkawa S, Okusaka T, Isayama H, et al. Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer. Br J Cancer. 2015 [Apr 28];112(9):1428–1434. doi:10.1038/bjc.2015.103. Epub 2015 Apr 16.
   PubMed Web of Science ®Google Scholar
• Boeck S, Weigang-Köhler K, Fuchs M, et al. Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial. Ann Oncol. 2007;18(4):745–751. Epub 2007 Jan 17.
   PubMed Web of Science ®Google Scholar
• Oettle H, Arnold D, Esser M, et al., et al. Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma. Anticancer Drugs. 2000 Sep;11(8):635–638.
   PubMed Web of Science ®Google Scholar
• Androulakis N, Syrigos K, Polyzos A, et al. Oxaliplatin for pretreated patients with advanced or metastatic pancreatic cancer: a multicenter phase II study. Cancer Invest. 2005;23(1):9–12.
   PubMed Web of Science ®Google Scholar
• Boeck S, Wilkowski R, Bruns CJ, et al. Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer. Oncology. 2007;73(3–4):221–227. doi:10.1159/000127413. Epub 2008 Apr 17.
   PubMed Web of Science ®Google Scholar
• Bodoky G, Timcheva C, Spigel DR, et al. A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. Invest New Drugs. 2012;30:1216–1223.
   PubMed Web of Science ®Google Scholar
• Ko AH, Tempero MA, Bekaii-Saab TB, et al. Dual MEK/EGFR inhibition for advanced, chemotherapy-refractory pancreatic cancer: a multicenter phase II trial of selumetinib (AZD6244; ARRY-142886) plus erlotinib. J Clin Oncol. 2013;31 Suppl:Abstract4014.
   Google Scholar
• Chung VM, McDonough SL, Philip PA, et al. SWOG S1115: randomized phase II trial of selumetinib (AZD6244; ARRY 142886) hydrogen sulfate (NSC-748727) and MK-2206 (NSC-749607) vs. mFOLFOX in pretreated patients (Pts) with metastatic pancreatic cancer. J Clin Oncol. 2015;33(suppl):abstr 4119.
   Google Scholar
• Hurwitz HI, Uppal N, Wagner SA, et al. Randomized, double-blind, phase II study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failed. J Clin Oncol. 2015 [Dec 1];33(34):4039–4047. doi:10.1200/JCO.2015.61.4578. Epub 2015 Sep 8.
   PubMed Web of Science ®Google Scholar
• Drummond DC, Meyer OM, Hong K, et al. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev. 1999;51:691–743.
   PubMed Web of Science ®Google Scholar
• Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004 [Mar 19];303(5665):1818–1822.
   PubMed Web of Science ®Google Scholar
• Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994 [Feb 15];54(4):987–992.
   PubMed Web of Science ®Google Scholar
• Krishna R, Webb MS, St Onge G, et al. Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties. J Pharmacol Exp Ther. 2001 Sep;298(3):1206–1212.
   PubMed Web of Science ®Google Scholar
• Allen TM, Newman MS, Woodle MC, et al. Pharmacokinetics and anti-tumor activity of vincristine encapsulated in sterically stabilized liposomes. Int J Cancer. 1995;62:199–204.
   PubMed Web of Science ®Google Scholar
• Webb MS, Harasym TO, Masin D, et al. Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br J Cancer. 1995;72:896–904.
   PubMed Web of Science ®Google Scholar
• Kawato Y, Aonuma M, Hirota Y, et al. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 1991 [Aug 15];51(16):4187–4191.
   PubMed Web of Science ®Google Scholar
• Lee W, Lockhart AC, Kim RB, et al. Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development. Oncologist. 2005 Feb;10(2):104–111.
   PubMed Web of Science ®Google Scholar
• Akimoto K, Kawai A, Ohya K. Kinetic studies of the hydrolysis and lactonization of camptothecin and its derivatives, CPT-11 and SN-38, in aqueous solution. Chem Pharm Bull. 1994;42:2135–2138.
   Web of Science ®Google Scholar
• Drummond DC, Noble CO, Guo Z, et al. Development of a highly active nanoliposomal irinotecan using a novel intra liposomal stabilization strategy. Cancer Res. 2006 [Mar 15];66(6):3271–3277.
   PubMed Web of Science ®Google Scholar
• Kang MH, Wang J, Makena MR, et al. Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing’s family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression. Clin Cancer Res. 2015;21(5):1139–1150. doi:10.1158/1078-0432.CCR-14-1882.
   PubMed Web of Science ®Google Scholar
• Chang TC, Shiah HS, Yang CH, et al. Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients. Cancer Chemother Pharmacol. 2015 Mar;75(3):579–586. doi:10.1007/s00280-014-2671-x. Epub 2015 Jan 11.
   PubMed Web of Science ®Google Scholar
• Rothenberg ML, Kuhn JG, Burris HA 3rd, et al. Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol. 1993 Nov;11(11):2194–2204.
   PubMed Web of Science ®Google Scholar
• Rivory LP, Haaz MC, Canal P, et al. Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials. Clin Cancer Res. 1997 Aug;3(8):1261–1266.
   PubMed Web of Science ®Google Scholar
• Araki K, Fujita K, Ando Y, et al. Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer. Cancer Sci. 2006;97:1255–1259. doi:10.1111/j.1349-7006.2006.00321.x.
   PubMed Web of Science ®Google Scholar
• Minami H, Sai K, Saeki M, et al. Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genomics. 2007;17:497–504. doi:10.1097/FPC.0b013e328014341f.
   PubMed Web of Science ®Google Scholar
• Chen LT, Shiah HS, Lin PC, et al. Phase I study of biweekly liposome irinotecan (PEP02, MM-398) in metastatic colorectal cancer after first-line oxaliplatin-based chemotherapy. J Clin Oncol. 2012;30(4):abstr 613.
   Google Scholar
• Roy AC, Park SR, Cunningham D, et al. A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Ann Oncol. 2013 Jun;24(6):1567–1573. doi:10.1093/annonc/mdt002. Epub 2013 Feb 13.
   PubMed Web of Science ®Google Scholar
• Chabot GG, Abigerges D, Catimel G, et al. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann Oncol. 1995;6:141–151.
   PubMed Web of Science ®Google Scholar
• Chabot GG. Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet. 1997 Oct;33(4):245–259.
   PubMed Web of Science ®Google Scholar
• Ko AH, Tempero MA, Shan Y-S, et al. A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. Br J Cancer. 2013 [Aug 20];109(4):920–925. doi:10.1038/bjc.2013.408. Epub 2013 Jul 23.
   PubMed Web of Science ®Google Scholar
• Wang-Gillam A, Li CP, Bodoky G, et al. NAPOLI-1 study group. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2015 [Nov 20]:pii: S0140-6736(15)00986-1. doi:10.1016/S0140-6736(15)00986-1. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Ramanathan RK, Korn RL, Sachdev JC, et al. Pilot study in patients with advanced solid tumors to evaluate feasibility of ferumoxytol (FMX) as tumor imaging agent prior to MM-398, a nanoliposomal irinotecan (nal-IRI). [Abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5–9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014; 74(19Suppl):Abstract nr CT224. doi:10.1158/1538-7445.AM2014-CT224
   Google Scholar
• Mollenhauer J, Roether I, Kern HF. Distribution of extracellular matrix proteins in pancreatic ductal adenocarcinoma and its influence on tumor cell proliferation in vitro. Pancreas. 1987;2:14–24.
   PubMedGoogle Scholar
• Watanabe I, Hasebe T, Sasaki S, et al. Advanced pancreatic ductal cancer: fibrotic focus and beta-catenin expression correlate with outcome. Pancreas. 2003 May;26(4):326–333.
   PubMed Web of Science ®Google Scholar
• Neijzen R, Wong MQ, Gill N, et al. Irinophore C™, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer. J Control Release. 2015 [Feb 10];199:72–83. doi:10.1016/j.jconrel.2014.11.031. Epub 2014 Dec 8.
   PubMed Web of Science ®Google Scholar
• Verreault M, Wehbe M, Strutt D, et al. Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma. J Control Release. 2015 [Dec 28];220(Pt A):348–357. doi:10.1016/j.jconrel.2015.10.053. Epub 2015 Nov 1.
   PubMed Web of Science ®Google Scholar
• Zhang L, Cao D-Y, Wang J, et al. PEG-coated irinotecan cationic liposomes improve the therapeutic efficacy of breast cancer in animals. Eur Rev Med Pharmacol Sci. 2013 Dec;17(24):3347–3361.
   PubMed Web of Science ®Google Scholar
• Yang C, Fu ZX. PEG-liposomal oxaliplatin combined with nuclear factor-κB inhibitor (PDTC) induces apoptosis in human colorectal cancer cells. Oncol Rep. 2014 Oct;32(4): 1617–1621. doi:10.3892/or.2014.3336. Epub 2014 Jul 17.
   PubMed Web of Science ®Google Scholar